Fig. 10.

Effect of Diac and/or 5-FU for 7 weeks on the colonic CD31 immuno-histochemical staining in DMH-induced CRC rats. Section of (a) CONT shows normal colonic epithelium with normal expression of CD31, whereas section of (b) CRC reveals excessive CD31 immunoreactivity in colon mucosa and in newly formed blood vessels in the submucosa. Sections of (c) 5-FU and (d) Diac treated groups show moderate CD31 immunoreactivity, while that of (e) 5-FU+Diac shows subtle CD31immunoreactivity. Panel (f) represents % of stained area, where data are illustrated as means ± SD (n = 6 animals/group) and analyzed using one-way ANOVA followed by Tukey’s Multiple Comparison test; P < 0.05. As compared with (*) CONT, (#) CRC, (@) 5-FU and (ϕ) Diac-treated groups. Treatments started on week 16 after DMH administration and lasted for 7 weeks, where Diac was gavaged daily and 5-FU was injected once weekly. ANOVA: analysis of variance; CD31: cluster of differentiation 31; CONT: control; CRC: colorectal cancer; Diac: Diacerein; 5-FU: 5-fluorouracil.